PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10051052-2	1999	This finding was accompanied by a corresponding reduction of the inactive glucuronide metabolite of MPA (MPAG) in patients, suggesting that tacrolimus may effect the conversion of MPA to MPAG by the enzyme UDP-glucuronosyltransferase (UDPGT).	Tacrolimus	140-150	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	206-233	
10051052-2	1999	This finding was accompanied by a corresponding reduction of the inactive glucuronide metabolite of MPA (MPAG) in patients, suggesting that tacrolimus may effect the conversion of MPA to MPAG by the enzyme UDP-glucuronosyltransferase (UDPGT).	Tacrolimus	140-150	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	235-240	
10051052-8	1999	The addition of clinically relevant concentrations of CsA (200-1,000 ng/mL) or tacrolimus (10-25 ng/mL) resulted in a dose-dependent inhibition of the UDPGT enzyme by both agents with tacrolimus, which was approximately 60-fold more efficient as an inhibitor.	Tacrolimus	79-89	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	151-156	
10051052-8	1999	The addition of clinically relevant concentrations of CsA (200-1,000 ng/mL) or tacrolimus (10-25 ng/mL) resulted in a dose-dependent inhibition of the UDPGT enzyme by both agents with tacrolimus, which was approximately 60-fold more efficient as an inhibitor.	Tacrolimus	184-194	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	151-156	
10051052-9	1999	The calculated inhibition constants (KI) of tacrolimus and CsA for the purified UDPGT were 27.3+/-5.6 ng/ml and 2,518+/-1473 ng/ml.	Tacrolimus	44-54	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	80-85	
10051052-12	1999	This finding suggested that the significantly more efficient inhibition of UDPGT by tacrolimus may occur by a more complicated mechanism that is yet to be determined.	Tacrolimus	84-94	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	75-80